Presently glioblastomas are incurable brain tumors. The prospect of treating this deadly disease has been the major justification for the current programs of boron neutron capture therapy (BNCT) throughout the world. However, based on pharmacological and cell biological considerations, it is improbable that BNCT will ever be an effective therapy for this tumor.
Introduction
Boron neutron capture therapy (BNCT) has been hailed as a "promising and possibly curative method" (1) for treating glioblastoma (GB), as well as one that might make microscopic radiosurgery a reality (2). Without question, BNCT exploits a unique physical principle, the high capture cross section of boron-10 nuclei for thermal neutrons. BNCT is based on the following nuclear reaction: n th + 10 B → 4 He + 7 Li + 2.3 (2.8) MeV and requires a two-step therapeutic process. In the first step, a boron-containing compound, which by itself has no cytocidal activity, is administered to the patient. When irradiated with thermal neutrons (E < 0.5 eV) the latter are captured by the boron nuclei, which in turn decay instantaneously. A helium-4 (i.e., alpha particle) and a lithium-7 nucleus are the resulting fission products. Within one cell diameter (< 10 μm), these highly energetic particles transfer all their kinetic energy to surrounding matter. Their initial linear energy transfer (LET) of ≈ 230 keV/μm confers a maximum biological effectiveness, and a high probability to cause cell death (for review, cf. e.g., 3).
Although an attractive concept, pharmacological and cell biological arguments suggest that it is unlikely that BNCT will be an effective therapy for glioblastoma.
Discussion

BNCT Limitations Based on Pharmacology
For BNCT to kill brain tumor cells, these cells must concentrate boron-containing compounds preferentially over normal cells. More than 50 years have passed since the first glioblastoma patients were treated at the Brookhaven National Laboratory (4), but the issue of the boron delivery agent is still unsolved (for recent BSH is a heavily boronated (12 boron atoms per molecule) sulfhydryl-or mercaptoborate, which does not cross the blood-brain barrier (BBB). Such a drug cannot be expected to be concentrated by tumor cells that have infiltrated normal brain with an intact BBB. The necessary boron concentration is probably not achieved in poorly perfused tumors with an abnormal BBB either (7). However, both of these conditions exist in virtually all glioblastomas.
BPA, a derivative of tyrosine, has to be administered as a fructose complex to overcome its low solubility in water. It appears to be actively transported across the cell membrane by the L-amino acid transport system (8), which leads to an improved tumor-to-blood ratio of approximately 2-4, as compared to ≈ 1 for BSH. In contrast to BSH, however, it contains only one boron atom per molecule. Hence, at least a three-fold higher dose has to be administered to achieve similar tumor boron concentrations as with BSH.
A substance whose distribution between tumor and blood is equal cannot be considered tumor-seeking. BPA is, in this respect, slightly better than BSH, but the selectivity is still limited.
For many new BNCT agents, synthesis and chemical characterization have barely been performed. Factors such as biological activity, stability, pharmacokinetics, and toxicity -factors which have prevented many potential boron carriers before from entering clinical phase, remain unresolved (for a recent review cf. e.g., 5).
Another pharmacological challenge is the requirement of a uniform cellular drug distribution at a high level. A boron threshold concentration of approximately 10 9 atoms per target cell is necessary to ensure an average capture of one neutron per cell (9). Biodistribution studies have confirmed such levels only in parts of the main tumor mass. In particular, when the infusion time of the boron compound is short, the heterogeneity of GB becomes obvious. Boron accumulation of tumor cells can then vary by a factor of 10 (10, 11).
In 9L gliosarcoma rats, the BBB had to be osmotically disrupted and high doses of BPA (125 mg/kg/h) had to be infused for 24 h continuously to achieve concentrations in the isolated tumor cell clusters approximating those in the main tumor (7). In humans, it seems that simply increasing the BPA dose and infusion time may cause more toxicity rather than improved therapeutic outcome (12).
To target all cells of a tumor using a single drug, and to achieve a homogeneous drug distribution in a heterogeneous tumor, are challenges not yet solved for any human tumor. When a non-toxic targeting substance that crosses the BBB and is selectively enriched in the tumor is found, BNCT will likely be dispensable. Other binary approaches, e.g., the use of radiosensitizers and external beam radiotherapy could be used at a fraction of the cost. Alternatively, such a targeting molecule could be radioactively labeled and targeted to destroy the tumor cells, similar to the therapy of differentiated thyroid cancer with radioiodine.
BNCT Limitations Based on Cell Biology
As has been pointed out, every tumor cell has to accumulate approximately 10 9 boron atoms in order to capture just one incident thermal neutron. With an average cell volume of 1 picoliter, this corresponds to an intracellular boron concentration of approximately 2 mM. This intracellular enrichment stands in sharp contrast to the typical nanomolar and micromolar drug concentrations used in clinical oncology and has not yet been achieved by other targeting mechanisms. Appropriately, the authors of a recent review on animal models for BNCT called the uniform accumulation of boron in the residual tumor cells infiltrating the normal brain "the most daunting challenge" for researchers in this field (13). Could boronated antibodies or other targeting molecules to tumor cell surface structures help to improve the situation? Probably not. First, the universal, tumor-specific marker protein that each and every glioblastoma cell expresses has not yet been discovered. Second, even if such a molecule existed, the required boron content of 10 9 atoms per cell would argue against such an approach. Densities of cell surface antigens are approximately 30,000/μm 2 for the most abundant, and are typically in the order of a few thousand per μm 2 (9). Translated into cell level this corresponds to approximately 10 4 -10 6 molecules per cell surface. Each targeting molecule would have to be labeled with 10 3 -10 5 boron-10 atoms. This is unlikely without loss of specificity when conventional boron carriers, such as carboranes are attached. The use of cascades of labeled targeting molecules is theoretically conceivable, but also improbable in practice because they would have to be pushed to complete saturation (14).
Experimental data which claim that a heavily boronated macromolecule (approx. 1000 B/molecule) linked to the epidermal growth factor (EGF) could be used to specifically target EGFR-positve tumor cells in vivo seem to refute what has just been stated (15). Indeed, 24 h after intratumoral injection of the bioconjugate, rats with the strongly EGFR-expressing F98 EGFR tumor (5 × 10 5 EGFR/cell) retained about one third of the injected boron. But the tumor tisssue of EGFR-negative controls also had approx. 15% of the boron dose. The twofold difference (21.1 vs. 9.2 μg/g) is certainly not an indication for a significant receptor affinity of the agent. Controls comparing the intratumoral injection mode of the boron agent under non-targeting conditions, i.e., with unlinked EGF or without EGF, were not reported. Compared to systemic iv application of BPA, the local injection of the EGF conjugate did not yield a higher boron concentration in the tumor (21.1 vs. 20.8 μg/g), but possibly in the brain (5.6 vs. 4.6 μg/g).
If, despite all difficulties, an antibody or a mix of cell-selective agents could be loaded with the necessary amount of boron and it could find its way past the reticuloendothelial system and BBB, it would have to clear a further biological hurdle: Internalization into the tumor cell. Monte Carlo simulations have revealed that extracellular boron has a greatly reduced effect on cell killing as compared to the same amount of boron uniformly distributed inside the cell or even concentrated in the cell nucleus (16-17). To fully exploit the destructiveness of the neutron capture reaction, transport of the boron agent into the target cell is, therefore, necessary.
The same "magic" agent labelled, for example, with a shortlived, low-energy electron-emitting radioisotope would not suffer from this handicap. Having a half-value thickness in tissue in the mm range (18), one would not have to worry about a strong radiation gradient within a cell diameter.
Problems with the Published BNCT Literature
For many years survival data of BNCT patients with histologically different brain tumors were collectively presented, giving the impression the data held for GB patients, too. The treatment results of seemed particularly impressive. Ten percent 10-year survival and even 29% survival for patients with superficial tumors sounded very promising (Table I) . However, patients who died within 30 days after surgery were excluded from the statistics, and the histopathology of the tumors was kept diffuse (19). The terms "malignant gliomas," "grade III & IV gliomas," and "glioblastomas" were frequently interchanged. It is common knowledge that gliomas of different grades are associated with very different life expectancies. Without partitioning, such data are meaningless. The Hatanaka Group stated the importance of proper histological typing, but continued publishing mean values of their mixed collective (20-21). Their survival rates for "glioblastoma" then became overstated even further by others (e.g., 22-23).
The Hatanaka Group claimed a number of cures of glioblastoma patients after BNCT (19). Unfortunately, this must be interpreted with great skepticism. As mentioned above, BSH does not cross the blood-brain barrier, infusion time was short (≈1 h) and the BNCT irradiation was typically in a single session. It is highly improbable that under these conditions the tumor cells, in particular those cells infiltrating normal brain, accumulated sufficient boron compound to permit an effective BNCT. Considering the lack of selectivity of BSH, it is contrary to radiobiological experience that all tumor cells could be killed by a single fraction of thermal neutrons, while the tolerance of the surrounding normal tissue was not exceeded. Finally, doubt is also indicated because of the generous classification habits. In a small group of 13 American patients who had been treated for "glioma" with BNCT in Japan, Laramore and Spence found one lymphoma patient. The median survival of 10 glioblastoma patients was 10.5 months, the longest survival lasted 26 months (24).
After the death of Dr. Hatanaka, his long-time collaborator Yoshinobu Nakagawa reexamined the results and reclassified the tumor entities. With 11% of GB patients surviving 2 years (20) and 9% living longer than 3 years (25) the numbers were much less spectacular. Unfortunately, even in these more recent publications there was still a tendency to present survival data from mixed histologies, and again the statistics showed an exclusion bias. Patients who died within the first 3 months after BNCT did not appear in the calculation of survival time. It is becoming increasingly difficult to justify further BNCT studies on patients with glioblastoma in light of these disputable results.
In fact, some recent reviews have been more modest in describing the treatment results of BNCT. According to Barth et al. (5) the "best survival data" from BNCT studies are comparable with those from current standard therapy. The best survival data of BNCT studies, however, should instead be superior to those of standard therapy because the patients admitted to BNCT are highly selected. Their tumors are predominantly superficial, at least partially resected, and the patients need to have a high performance status (cf. e.g., 19, 25-27) . These criteria apply to fewer than half of the patients with GB and such patients have a better prognosis, per se (23). BNCT eligibility criteria are similar to those for brachytherapy. With 2-year survival rates of > 40% and 5-year survival of ≥ 10%, brachytherapy, in fact, achieves significantly better long-term results than standard therapy (e.g., 29-30).
In a recent commentary, the possibility of a selection bias in BNCT patients was admitted, as well (12). However, the authors concluded that because of the bias it could not be decided whether the clinical BNCT results were "equivalent or superior" to conventional irradiation. From the aforementioned, it should be clear that the point of superiority is moot. The general eligibility criteria for BNCT and the inclusion of non-GB gliomas into the patient cohorts are factors that increase rather than decrease the average survival time.
Proponents of BNCT around the world continue to praise it as an "exciting and innovative form of treatment," which for certain types of tumors could "replace conventional radiotherapy." According to a recent press release by the Joint Research Centre in Petten (the Netherlands) clinical trials for the treatment of glioblastoma "have increased patient survival times and show no contra-indications" (31). A review on BNCT published by members of the same group, however, noted that "no real remission nor any increased survival has yet been shown" (1) . Serious side effects and "progressive deterioration after BNCT" were reported from a Swedish phase 2 study in May 2006 (32). Three months after appearance, the article was retracted without comment.
From Table I it can be seen that the radiation conditions of the various clinical studies were quite different. The reactors where BNCT has been performed differ in power, neutron flux, energy spectrum, beam contaminants, et cetera.
In addition, size and number of treatment fields or number of fractions varied. These differences in the treatment protocols complicate or preclude comparisons of experimental and clinical work -not only for GB. Gupta et al. (6) urged the BNCT community to standardize each aspect of the design, implementation, and reporting of clinical studies. This appeal can be extended to preclinical research, as well. Finally, it should be a matter of course that all clinical results -good or bad -be promptly and candidly reported in the open biomedical literature (12).
Conclusion
Although BNCT has been used for five decades, first principles suggest failure. Clinical success is lacking and the cost of the therapy is a multiple of other treatment modalities.
To date, the concentration of boron in individual tumor cells remains unknown (11), and common standards regarding BNCT dosimetry do not exist (33). Controlled randomized studies that might have objectively demonstrated any advantages have not been performed.
Before new facilities are anticipated or old ones converted, BNCT trials should be carried out in the existing units, preferably by a strong international cooperative group. However, if the actual programs fail again to find a dose-effect correlation and more convincing treatment results, BNCT for GB might not be worth pursuing. Possibly as a precautionary measure in case of such failure, proponents of BNCT have already asked for "removal of GBM sterilization as the most desirable and highly sought goal for BNCT" (14).
